I wouldn't put too much emphasis on the CEO's age, he is not the founder, and a new CEO can readily step into his shoes. What I would focus on are the new SAAS offerings, especially those that improve patient
outcomes while lowering costs. The End Stage Renal Disease product is just being introduced and could be very valuable to payor organizations seeking to identify sick patients before they crash. That product is unique and ought to attract the attention of a suitor (not to mention it can be rolled out to other disease states as well).